ArticleThe Lancet regional health. Southeast Asia2025
Effect of antiretroviral therapy on retention of people living with HIV in India (2012-2017): a retrospective, cohort study.
Article in The Lancet regional health. Southeast Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Misinformation, Social Media, and Myths About Injectable ART: Communication Barriers to HIV Care Among Transgender Women in India.AIDS and behavior · 2026Article
- Clarifying methodological discrepancies in HIV retention analysis-authors' reply.The Lancet regional health. Southeast Asia · 2025Article
- Methodological discrepancies in HIV retention analysis.The Lancet regional health. Southeast Asia · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: India's free antiretroviral therapy (ART) programme was initiated in 2004. People living with HIV who were registered with ART centres (ARTC) were initiated on ART based on the CD4 count cutoffs as per prevailing guidelines. The others with higher counts remained on six-monthly follow up. We estimated retention rates among people living with HIV receiving ART in the programme and their determinants during 2012-2017. Methods: In this retrospective cohort study, the records of people living with HIV aged ≥15 years, registered between April 2012 and March 2017 (reference period) in 81 of 396 ARTC across 33 Indian states were reviewed. 'People living with HIV not on ART' were defined as all those who were registered but not eligible for ART initiation or not started ART through the reference period. 'People living with HIV on ART' were those who were already on ART or initiated on ART as per prevailing guidelines. Relevant data from the clinic records were extracted and analysed for 'Not on ART' and 'On ART' groups separately using life-table method, Cox proportional hazards model to estimate retention probability and potential determinants. Findings: Of 154,154 registered people living with HIV, 82.3% received ART ('on ART') during 2012-2017. Proportion retained was lower among 'not on ART' vs 'on ART' people living with HIV and was statistically significant (71.1% vs 88.9%, p < 0.001). Five-year retention probability was 57% for 'not on ART' and 81% for 'on-ART' people living with HIV (p < 0.001). The incidence of cases who were lost to follow up was 12.9 and 4.3/100 person-years among 'not on ART' & 'on ART' people living with HIV, respectively. Determinants of becoming lost to follow up (Adjusted HR, 95% CI) included 'being in not on ART' (Adjusted HR: 2.95, 95% CI: 2.85-3.05) 'being male' (1.08, 1.05-1.11); 'having CD4 count 351-500 cells/mm Interpretation: New programmatic strategies for improving retention of people living with HIV in care may benefit by focussing on males, younger ages (15-29 years), CD4 counts during registration, history of or new TB diagnoses and early intervention within the first year. Funding: This study was supported with NOA# SAMS/NACP/IE-ART/NARI/2017/09 dated March 27, 2017, awarded by Strategic Alliance Management Services Pvt. Ltd. (SAMS) with funding support from the Global Fund.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.